Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, has announced the completion of a merger in which the company has become a wholly-owned subsidiary of HLB Innovation, a publicly traded company in South Korea and a member of the HLB Group.

The merger certificate is expected to be filed shortly. The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.

"We are thrilled to take this next step with HLB Innovation as our parent company. This merger not only strengthens our resources by leveraging HLB Group's dynamic bio-ecosystem, but also enhances our ability to rapidly advance our clinical pipelines. We're confident that with HLB Innovation's backing, Verismo is well-positioned to bring transformative therapies to areas of unmet medical need," said Bryan Kim, Chief Executive Officer of Verismo Therapeutics.

The HLB Group, which has a diverse portfolio that spans biopharma, medical devices, healthcare, lifestyle, and other sectors, previously held a majority stake in Verismo. This merger aligns with HLB Group's strategic commitment to expanding its capabilities in next-generation cell therapies.